GSK plc (NYSE:GSK) Shares Bought by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. grew its holdings in shares of GSK plc (NYSE:GSK) by 100.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,406 shares of the pharmaceutical company’s stock after purchasing an additional 16,713 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in GSK were worth $1,130,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the period. Hotchkis & Wiley Capital Management LLC grew its holdings in shares of GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares during the period. Miller Howard Investments Inc. NY acquired a new stake in shares of GSK in the 4th quarter worth approximately $23,366,000. Finally, Bridgewater Associates LP grew its holdings in shares of GSK by 107.3% in the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock worth $39,483,000 after acquiring an additional 500,010 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 2.0 %

Shares of GSK stock opened at $40.08 on Friday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm has a market cap of $83.07 billion, a PE ratio of 25.21, a P/E/G ratio of 1.12 and a beta of 0.58. The business’s fifty day moving average is $35.47 and its two-hundred day moving average is $37.20. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts anticipate that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.